The introduction of a 750mcg teriparatide injection in Australia has been cautiously managed, with distribution primarily to specialist clinicians and designated clinics . Initial market uptake for this increased strength remain unavailable from the manufacturer , although experts suggest gradual adoption rates . Availability to patients is dictate